Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (CLLS) presented preclinical data for .HEAL-101, its gene-editing candidate for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress.
The candidate targets APOC3, a driver of elevated triglycerides. In human liver cells, mean editing was approximately 90%, without DNA double-strand breaks at the target site. In mice with humanized livers and normal lipid levels, a single intravenous injection achieved approximately 65% mean human APOC3 editing, reaching up to 70%. In a separate mouse disease model, APOC3 fell 67% ± 12% (mean ± standard deviation); single-dose triglyceride reduction was highlighted at 76%. Editing was detected in the liver, with no significant activity in other tissues analyzed.
Cellectis plans a Phase 1 investigator-initiated trial in China, with preliminary clinical data expected in the second half of 2027.
Cellectis (CLLS) reported its monthly share capital and voting rights totals as of September 30, 2026.
The company had 100,732,781 shares in its capital and 105,563,044 voting rights on that date. The disclosure falls under Article 223-16 of the French financial markets authority’s General Regulation.
Cellectis (CLLS) approved a strategic transformation on September 11, 2026 to focus on becoming an in vivo gene editing company targeting chronic metabolic diseases.
The company will prioritize two lead programs: .HEAL-101, a base-editing therapy targeting APOC3 for severe hypertriglyceridemia, and .HEAL-201, an epigenetic editing therapy targeting PCSK9 for severe hypercholesterolemia. Both are delivered via lipid nanoparticles and have shown high on-target activity and substantial APOC3 or PCSK9 reductions, as well as triglyceride lowering in humanized murine models. Phase 1 investigator-initiated trials in China are planned, with preliminary data expected in H2 2027 for .HEAL-101 and H1 2028 for .HEAL-201.
Cellectis will exit internal development of lasme-cel and eti-cel, seek partners for these assets, support existing cell therapy partnerships, and realign operations to extend its cash runway into H2 2028. Trading on Euronext Growth Paris will be temporarily halted on September 14, 2026, and management will host English and French webcasts the same day.
Cellectis (CLLS) will host English- and French-language conference calls and webcasts on September 14, 2026 to provide a business update.
The English session is scheduled for 8:00 a.m. ET / 2:00 p.m. CET, accessible via webcast at https://viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480 or by phone at +1 (800) 717 1738, +1 (646) 307 1865, and France toll-free at +33 (800) 945 120. The French session will follow at 9:00 a.m. ET / 3:00 p.m. CET, with access via webcast at https://viavid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca and the same dial-in numbers.
A replay will be made available on the company’s website after the event.
Cellectis (CLLS) reported its monthly share capital and voting rights as of August 31, 2026, in line with Article 223-16 of the French financial markets authority.
The company had 100,718,974 shares outstanding and a total of 105,568,956 voting rights on that date. The shares are listed on Euronext Growth under ISIN code FR0010425595.
Cellectis (NASDAQ: CLLS), a clinical-stage gene-editing company, announced participation in several upcoming investor conferences. These include the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10, 2026, the Baird 2026 Global Healthcare Conference in New York on September 15, 2026 (with a company presentation from 12:50 to 1:20 p.m. ET), Barclays Biotech 1x1 Day in New York on October 6, 2026, the Stifel 2026 Healthcare Conference in New York from November 10-12, 2026, and the Jefferies Global Healthcare Conference in London from November 16-19, 2026. Cellectis’ management will be available for investor meetings at these events, and any available webcasts will be posted in the investors section of its website.
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) reported second-quarter 2026 results and clinical updates for its allogeneic CAR-T pipeline. Lasme-cel in r/r B-ALL received FDA RMAT designation based on BALLI-01 Phase 1 data showing 100% ORR (7/7) and 57% CR/CRi in the target Phase 2 population, with low rates of grade ≥3 CRS and ICANS (4% each) and IEC-HS (2%), all resolving. A pivotal Phase 2 BALLI-01 trial is ongoing, with first interim analysis expected in Q4 2026 and new country authorizations in the UK, France, Italy and Spain.
Eti-cel in r/r B-NHL showed 88% ORR and 63% CR in the optimal dose cohort of NATHALI-01, with translational data guiding alemtuzumab dosing and IL-2 strategies; a full Phase 1 dataset is expected in Q4 2026. Cash, cash equivalents and fixed-term deposits totaled $169 million at June 30, 2026, which Cellectis believes will fund operations into Q4 2027. For the first half of 2026, revenues and other income were $14.5 million versus $30.2 million a year earlier, while net loss attributable to shareholders narrowed to $39.6 million (loss per share $0.39) from $41.9 million ($0.42). Adjusted net loss improved to $35.6 million from $39.6 million, supported by a swing in net financial result from an $18.1 million loss to a $9.2 million gain, despite higher R&D and SG&A expenses.
Cellectis (CLLS) released its monthly disclosure under Article 223-16 of the French financial markets authority, detailing share capital and voting rights. As of July 31, 2026, the company reported 100,701,207 shares outstanding and a total of 105,554,794 voting rights.
The listing market is Euronext Growth, and the company’s ISIN code is FR0010425595. Cellectis also provided dedicated media and investor relations contacts for further information on this voting rights update.
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) announced it will report its second quarter 2026 financial results, for the period ended June 30, 2026, on Thursday, August 6, 2026 after the close of the US market. The earnings press release will be available in the Investors section of the company’s website.
Cellectis noted it will not host a conference call to discuss these results. Investor questions can be directed to the company’s investor relations team at investors@cellectis.com. Cellectis is a clinical-stage biotechnology company focused on allogeneic CAR T immunotherapies and gene therapies, with headquarters in Paris and additional locations in New York and Raleigh.
Cellectis (CLLS) released its monthly information on share capital and voting rights under Article 223-16 of the French financial markets authority rules.
As of June 30, 2026, Cellectis reported 100,698,158 shares outstanding and a total of 105,551,650 voting rights on Euronext Growth.